TY - CHAP M1 - Book, Section TI - Antifolates A1 - Chabner, Bruce A. A2 - Chabner, Bruce A. A2 - Longo, Dan L. PY - 2016 T2 - Harrison's Manual of Oncology, 2e AB - The antifolates were introduced as antileukemic drugs in 1948; in landmark experiments treating children with acute lymphocytic leukemia (ALL), Sidney Farber produced the first evidence that chemotherapy with a folate analogue, aminopterin, could lead to complete remissions (1). Methotrexate subsequently became the standard antifolate in treatment of ALL. It has since gained an important role in regimens for lymphomas, and choriocarcinoma, and as an immunosuppressive following allogeneic bone marrow transplantation. It is also a standard agent for treating rheumatoid arthritis, Wegener's granulomatosis, and other inflammatory/autoimmune diseases. Pemetrexed (Alimta), a closely related structure but with a different site of action, is widely used for non-small cell lung cancer, mesothelioma, and ovarian cancer. Pralatrexate, the newest antifolate similar in action to methotrexate, is highly active against peripheral T-cell lymphoma and cutaneous T-cell lymphoma. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - hemonc.mhmedical.com/content.aspx?aid=1127646297 ER -